Search

Your search keyword '"Mühlfeld, Anja"' showing total 175 results

Search Constraints

Start Over You searched for: Author "Mühlfeld, Anja" Remove constraint Author: "Mühlfeld, Anja"
175 results on '"Mühlfeld, Anja"'

Search Results

2. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

3. Rescue Allocation Modes in Eurotransplant Kidney Transplantation: Recipient Oriented Extended Allocation Versus Competitive Rescue Allocation—A Retrospective Multicenter Outcome Analysis

4. A Privacy-Preserving Protocol for the Kidney Exchange Problem

5. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

6. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

7. Results of the prospective multicenter SoLKiD cohort study indicate bio-psycho-social outcome risks to kidney donors 12 months after donation

8. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

9. Rescue Allocation Modes in Eurotransplant Kidney Transplantation: Recipient Oriented Extended Allocation Versus Competitive Rescue Allocation-A Retrospective Multicenter Outcome Analysis

10. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

11. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

12. Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial

13. Rescue Allocation Modes in Eurotransplant Kidney Transplantation: Recipient Oriented Extended Allocation Versus Competitive Rescue Allocation—A Retrospective Multicenter Outcome Analysis

15. Kidney Transplantation after Rescue Allocation - The Eurotransplant Experience

16. Management of Immune Thrombotic Thrombocytopenic Purpura Without Therapeutic Plasma Exchange

17. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

18. Clinical Validation of a Novel ELISpot-based in Vitro Diagnostic Assay to Monitor CMV-specific Cell-Mediated Immunity in Kidney Transplant Recipients

19. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

20. Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study

21. Kidney Transplantation after Rescue Allocation - The Eurotransplant Experience:A Retrospective Multicenter Outcome Analysis

22. Rescue allocation and recipient oriented extended allocation in kidney transplantation—influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs

23. Results of the prospective multicenter SoLKiD cohort study indicate bio-psycho-social outcome risks to kidney donors 12 months after donation

24. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

25. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients

26. Contributors

34. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study

36. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

37. Time on previous renal replacement therapy is associated with worse outcomes of COVID-19 in a regional cohort of kidney transplant and dialysis patients

42. BTBR Ob/Ob Mutant Mice Model Progressive Diabetic Nephropathy

46. Additional file 1: of Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study

47. Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR)

49. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation

Catalog

Books, media, physical & digital resources